Drug Trial Radar · NCT05065970
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Aug 31, 2021
Primary completion
Feb 6, 2023
Study completion May 6, 2024
Sponsor
- Lead sponsor
- HI-Bio, A Biogen CompanyIndustry
- Sponsor type
- Industry
- First posted
- Oct 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN
Conditions
- Immunoglobulin A (IgA) Nephropathy
Interventions
FelzartamabDrug
anti-CD38+ monoclonal antibody
PlaceboOther
Placebo comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Relative Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) in 24-hour Urine at Month 9Time frame: Baseline, Month 9
Locations
59 sites in 15 countries. Site status is shown where the registry gives one.
FOMAT Medical Research - FOMAT - HyperCore - PPDS
Oxnard, California
Amicis Research Center, Vacaville
Vacaville, California
Mayo Clinic Hospital - Methodist Campus
Rochester, Minnesota
MedResearch INC
El Paso, Texas
Core Research Group
Milton, Queensland, Australia
Sunshine Hospital - Australia
Saint Albans, Victoria, Australia
Regionaal Ziekenhuis Jan Yperman VZW
Ieper, Belgium
CHU Sart Tilman Hospital
Liège, Belgium
Imelda VZW
Bonheiden, Antwerpen, Belgium
UZ Leuven Hospital
Leuven, Vlaams Brabant, Belgium
Medical Center Hera EOOD, Montana
Montana, Bulgaria
Medical Center Hipokrat- N EOOD
Plovdiv, Bulgaria
University Multiprofile Hospital for Active Treatment
Stara Zagora, Bulgaria
Diagnostic- Consultative Center Convex EOOD
Sofia, Sofia-Grad, Bulgaria
Nemocnice AGEL Novy Jicin a.s
Nový Jicín, Moravian-Silesian Region, Czechia
Eticka komise Fakultni nemocnice Olomouc
Olomouc, Olomouc Region, Czechia
Fakultni nemocnice Kralovske Vinohrady Hospital
Prague, Praha, Hlavní Mesto, Czechia
Vseobecna Fakultni Nemocnice V Praze
Prague, Praha, Hlavní Mesto, Czechia
JSC Evex Hospitals
Tbilisi, Georgia
L. Managadze National Center of Urology LTD
Tbilisi, Georgia
Tbilisi State Medical University's and Ingorokva's University Clinic of High Medical Technologies
Tbilisi, Georgia
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Germany
Medizinische Hochschule Hannover
Hanover, Lower Saxony, Germany
Universitätsklinikum Essen
Essen, North Rhine-Westphalia, Germany
National Hospital Organization Chibahigashi National Hospital
Chiba, Chiba, Japan
Hokkaido University Hospital
Sapporo, Hokkaidô, Japan
Hospital of the University of Occupational and Environmental Health, Japan
Kitakyushu-Shi, Hukuoka, Japan
Kurume University Hospital
Kurume-Shi, Hukuoka, Japan
Fukushima Medical University Hospital
Fukushima, Hukusima, Japan
JCHO Sendai Hospital
Sendai, Miyagi, Japan
Osaka University Hospital
Suita-Shi, Ôsaka, Japan
Japanese Red Cross Ashikaga Hospital
Ashikaga-Shi, Tochigi, Japan
Juntendo University Hospital
Bunkyō-Ku, Tokyo, Japan
University Malaya Medical Centre
Pantai, Malaysia
St Frances Cabrini Medical Center and Cancer Institute
Santo Tomas, Batangas, Philippines
Clinical Hospital Center Bezanijska Kosa
Belgrade, Serbia
Clinical Hospital Centar Zvezdara
Belgrade, Serbia
General Hospital Krusevac
Kruševac, Serbia
University Clinical Center Nis
Niš, Serbia
Clinical Centre of Vojvodina
Novi Sad, Vojvodina, Serbia
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.